Australian blood plasma giant CSL is to strengthen its footprint in China with a $352 million deal for an 80 per cent stake in a Chinese plasma factionator.
CSL will acquire the stake in Wuhan Zhong Yuan Rui De Biological Products Ruide from Humanwell Healthcare Group, a Shanghai-listed pharmaceutical company, CSL said in a statement on Tuesday. The deal is subject to regulatory approval.
The deal the first foreign purchase of a major Chinese blood producer underscores international appetite for a stake in China's fast-growing healthcare market and, according to one analyst, may open the way for more such deals.
CSL shares...
¬ Haymarket Media Limited. All rights reserved.
